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Abstract
Shigella spp. are among the enteric pathogens with the highest attributable incidence of moderate-
to-severe diarrhea in children under 5 years of age living in endemic areas. There are no vaccines 
available to prevent this disease. In this work, we investigated a new Shigella vaccine concept 
consisting of non-living, self-adjuvanted, Lactococcus lactis bacterium-like particles (BLP) 
displaying Shigella invasion plasmid antigen (Ipa) B and IpaD and examined its immunogenicity 
and protective efficacy in adult and newborn/infant mice immunized via the nasal route. Unique 
advantages of this approach include the potential for broad protection due to the highly conserved 
structure of the Ipas and the safety and practicality of a probiotic-based mucosal/adjuvant delivery 
platform. Immunization of adult mice with BLP-IpaB and BLP-IpaD (BLP-IpaB/D) induced high 
levels of Ipa-specific serum IgG and stool IgA in a dose-dependent manner. Immune responses 
and protection were enhanced by BLP delivery. Vaccine-induced serum antibodies exhibited 
opsonophagocytic and cytotoxic neutralizing activity, and IpaB/D IgG titers correlated with 
increased survival post-challenge. Ipa-specific antibody secreting cells were detected in nasal 
tissue and lungs, as well as IgG in bronchoalveolar lavage. Bone marrow cells produced IpaB/D-
specific antibodies and contributed to protection after adoptive transfer. The BLP-IpaB/D vaccine 
conferred 90% and 80% protection against S. flexneri and S. sonnei, respectively. Mice immunized 
with BLP-IpaB/D as newborns also developed IpaB and IpaD serum antibodies; 90% were 
protected against S. flexneri and 44% against S. sonnei. The BLP-IpaB/D vaccine is a promising 
candidate for safe, practical and potentially effective immunization of children against shigellosis.
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INTRODUCTION
A variety of new vaccine approaches are being explored to improve the safety and 
effectiveness of pediatric immunization. Methods that allow administration of vaccines 
through mucosal routes are highly desirable, as they are more practical, less invasive and 
easier to implement than parenteral injection, the route typically used for routine 
immunization. Effective mucosal vaccines that can prevent the devastating burden of 
childhood diarrhea in less developed areas of the world would make a substantial 
contribution to public health. The recent Global Enteric Multicenter Study (GEMS), led by 
the Center for Vaccine Development at the University of Maryland, identified Shigella as 
one of the organisms associated with the largest incidence of diarrheal disease in children 
under 5 years of age.1 When incidence of disease was stratified by age, toddlers 11–23 
months of age were found to be the most affected group.1 In addition to unacceptably high 
mortality rates, repeated bouts of diarrheal disease throughout childhood can result in 
impaired development and long-term disability.2,3 Aiming to identify an effective pediatric 
prophylactic tool to substantially reduce this burden, we focused on Shigella invasion 
plasmid antigens (Ipas), which are components of the Type III secretion system, as potential 
candidates for the development of a broadly protective subunit-based Shigella vaccine. We 
have recently shown that adjuvanted Shigella IpaB and IpaD were able to induce robust 
cross-protective immunity in mice immunized via mucosal4,5 or parenteral6,7 routes. The 
purpose of this study was to investigate the use of non-living Lactococcus lactis bacterium-
like particles (BLP) as an adjuvant and vaccine display system for mucosal delivery of 
Shigella IpaB and IpaD that could potentially be used to immunize susceptible children. The 
L. lactis BLP consist of peptidoglycan (PGN) shell particles devoid of intracellular content 
that are produced by heat-acid treatment of L. lactis. They have the same shape and size as 
the living L. lactis.8 Antigens are displayed on the particle surface as a fusion protein 
containing a PGN binding domain that attaches non-covalently and with high avidity to the 
PGN wall.8,9 Because L. lactis is a generally regarded as a safe (GRAS) food additive, the 
BLP are likely to be safe for immunization of children through a mucosal route. The BLP 
PGN is a Toll-like receptor 2 (TLR-2) agonist10 and serves as a mucosal adjuvant.11 
Because of their larger size (+/− 1–2 μm), the particles interact more efficiently with 
mucosal antigen-presenting cells (APC) and facilitate vaccine uptake. Conceptually, this 
approach would be highly advantageous because it combines safety, strong immunogenic 
capacity and ease of delivery for effective and practical immunization early in life. A 
precedent exists for efficient mucosal immunization of newborn mice with Yersinia pestis 
LcrV displayed on L. lactis BLP, which induced mucosal and systemic immunity and 
afforded complete protection against systemic plague infection.10 Likewise, the BLP 
technology has been successfully tested in adult mice as a vaccine delivery system for 
protection against respiratory syncytial virus12, malaria13 and Streptococcus pneumoniae.14 
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Serving as adjuvants, the BLP have been shown to enhance the immunogenicity15 and 
protective efficacy16,17 of intranasally (i.n.) delivered influenza virus vaccines.
Herein, we examined the in vivo distribution of i.n. delivered L. lactis BLP and the 
immunogenicity and protective capacity of combined BLP displaying IpaB or IpaD (BLP-
IpaB/D). Increasing doses of BLP-IpaB/D and IpaB/D alone were tested in adult and 
newborn mice, and a thorough characterization of the mucosal and systemic immune 
responses was performed, including a detailed analysis of serum antibodies along with their 
functional capacity and association with protection.
RESULTS
Shigella IpaB and IpaD displayed on L. lactis BLP
IpaB and IpaD PGN anchor fusion proteins (PA) were successfully produced and attached to 
the L. lactis BLP. The SDS-PAGE analysis of the vaccine preparations revealed bands near 
the 87 KDa and 64 KDa expected for the IpaB-PA fusion protein loaded onto the BLP and 
IpaB alone, respectively (Figure 1a). Bands in the proximity of the theoretical sizes of 61 
KDa and 38 KDa were seen for IpaD-PA loaded on the BLP and IpaD alone, respectively 
(Figure 1b). The IpaB and IpaD displayed on the BLP were recognized by specific 
monoclonal antibodies as shown by immunofluorescence images (Figure 1c); no signal was 
detected for the BLP alone.
In vivo distribution of L. lactis BLP
To assess the in vivo distribution of i.n. delivered BLP and identify mucosal tissues 
potentially involved in immunologic priming, fluorescently labeled BLP (fBLP) were 
administered to adult mice at a concentration equivalent to the highest dose used in the 
vaccine studies and following the same immunization procedures (described below). Mice 
that received unlabeled BLP served as negative controls. Whole body images were obtained 
every 2–4 h for 2 days. The fBLP were seen in the nasal cavity immediately after 
vaccination and most of the inoculum remained there for the next 2 h (Figure 2a and b); a 
small fraction (10%) was still detected in this compartment 4 h after inoculation but had 
completely disappeared at the 12 h time point. The majority of the particles reached the 
gastrointestinal tract (most likely due to swallowing reflex) 4 h after inoculation, with a 
fraction remaining for up to 24 h (Figure 2a and b). Although not evident from the whole 
body images, the fBLP also localized in the lung, as demonstrated by images of dissected 
tissue 24 h after inoculation (Figure 2a). Almost all of the fBLP had been cleared from the 
body 2 days after vaccination (Figure 2a and b).
Protective immunity induced by intranasal immunization with BLP-IpaB/D in adult mice
The immunogenicity and protective efficacy of the BLP-IpaB/D in comparison with IpaB/D 
(the proteins alone) was first examined in a dose-escalation experiment. Adult mice were 
immunized i.n. with increasing dosage levels of each of the vaccines on days 0, 14 and 28, 
as described in Materials and Methods and in the legend to Figure 3. Immunization with 
BLP-IpaB/D resulted in robust serum IgG responses to both IpaB and IpaD, which increased 
in a dose-dependent manner (Figure 3a). Mice that received the maximum (Max) dose of 
Heine et al. Page 3













BLP-IpaB/D (the largest amount that could be given in the 30-μl inoculum) were the first to 
respond; this group exhibited significant levels of IpaB and IpaD-specific IgG, above all 
other groups, after the first immunization. Mice that received the high, medium and low 
doses of BLP-IpaB/D responded only after the second vaccination. The influence of the 
vaccine dose in the magnitude of serum IgG responses was particularly noticeable at this 
time point (Figure 3a). Although titers increased and reached a plateau after the 3rd 
vaccination in all groups, the recipients of the BLP-IpaB/D Max dose remained the best 
responders throughout. The BLP-IpaB/D Max was also the only group that developed 
significant and sustained IpaB-specific IgA responses in stool (Figure 3b). Stool IgA 
responses against IpaD were also detected but did not follow a dose-response pattern. No 
antibodies were detected in serum or stool from BLP and PBS controls. Importantly, the IgG 
responses to IpaB and IpaD markedly improved when displayed on the BLP as compared to 
the proteins given alone. BLP-IpaB/D recipients achieved ~3 and 5 log10 higher IpaB and 
IpaD serum IgG titers, respectively, than those that received IpaB and IpaD alone. In fact 
only the group that received the max dose of IpaB and IpaD alone developed a response 
above the negative controls. Fecal IgA responses were absent following immunization with 
IpaB/D alone.
One month after vaccination all mice were subjected to a lethal pulmonary challenge with 
fully virulent S. flexneri strain 2a 2457T. Mice immunized with BLP-IpaB/D had the highest 
survival rates: 90% for those that received the maximum dose and 60% in the high and 
medium dose groups (Figure 3c). Protection was dramatically reduced when IpaB and IpaD 
were given alone: less than half (40%) of the mice that received the maximum dose survived 
and only 10% of those that received the high dose (statistically indistinguishable from the 
unvaccinated controls) survived. When challenged with wild-type S. sonnei, which together 
with S. flexneri 2a cause the majority of endemic pediatric shigellosis in the developing 
world, the BLP-IpaB/D Max dose afforded 80% protection; none of the other vaccine 
groups exhibited significant protection against this strain (Figure 3c). Negligent protection 
against S. sonnei and S. flexneri (≤20%) was seen occasionally in mice that received BLP 
alone, whereas all unvaccinated (PBS) controls succumbed to infection 6 to 8 days after 
challenge (Figures 3c and d). Results were consistent when different batches of vaccine 
were tested in separate experiments both in terms of kinetics of antibody production and 
BLP-immune enhancement (Figure 3d), as well as protective efficacy (Figure 3e).
IpaB- and IpaD antibodies and prediction of protection by titer and functional capacity
A detailed statistical analysis was performed to establish potential associations between 
vaccine-induced antibody responses (IgG, IgG1 and IgG2a in serum and IgA in stool) and 
protection against disease. First, survival rates post challenge were compared among mice 
immunized with BLP-IpaB/D or IpaB/D classified as responders vs. non-responders. Serum 
IgG titers ≥ 50 EU ml−1 and stool IgA titers ≥ 10 EU ml−1 were considered the threshold for 
a positive response (corresponding to 4 times the lower limits of detection, which was also 4 
times the titer for all unvaccinated controls) (Table 1). The proportion of survivors was 
significantly higher among mice that had developed positive responses for IgG and IgG2a 
against both IpaB and IpaD in serum and IgA against IpaB in stool, compared to non-
responders (P<0.05, two-sided Fisher exact test). Furthermore, there was a significant 
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association between survival and the magnitude of serum ELISA titers for each type of 
antibody measured (P<0.05, likelihood ratio test in logistic regression) (Table 1). 
Vaccinated mice that were protected from S. flexneri infection (i.e. healthy survivors that 
maintained at least 80% of body weight) had significantly higher serum IgG titers anti-IpaB 
and IpaD than those that succumbed to infection at the time of challenge (Figure 4a). A 
further analysis of vaccine-induced antibodies and probability of survival using logistic 
regression confirmed the association between IpaB- and IpaD-specific IgG and protection 
(P<0.001). The models indicated that an IpaB titer ≥1×106 EU ml−1 predicted at least an 
80% chance of survival (60% if the titer dropped to 1×105 EU ml−1) and an IpaD titer 
≥1×105 EU ml−1 predicted at least 60% probability of survival (Figure 4b).
Given the observed correlation between protection against disease and vaccine-induced 
humoral responses, we investigated the functional capacity of IpaB and IpaD antibodies in 
facilitating bacterial uptake by phagocytic cells and preventing Shigella-induced 
cytotoxicity. Antibodies induced by BLP-IpaB/D and IpaB/D exhibited opsonophagocytic 
activity (OPA) seen by the increased uptake of serum-opsonized S. flexneri 2a 2457T by 
mouse macrophages, compared to a non-opsonized organism or organisms opsonized with 
non-immune serum (Figure 4c). The highest OPA responses were seen in the group 
immunized with BLP-IpaB/D (Figure 4c). These results prompted us to examine the IgG 
subclass profile induced by the two vaccine treatments to test the hypothesis that the higher 
OPA could be associated with an increased proportion of antibodies with higher binding 
capacity for phagocytic cells. Indeed, higher IgG2a levels were produced after immunization 
with BLP-IpaB/D as compared to IpaB/D alone (Figure 4d). Additionally, we measured the 
capacity of vaccine-induced antibodies to neutralize macrophage cytotoxicity in the 
presence of wild-type Shigella. Sera from mice immunized with BLP-IpaB/D and IpaB/D 
prevented Shigella-induced cell death compared to non-immune sera from mice that 
received PBS (Figure 4e).
Mucosal ASC, antibodies and innate immune mediators in bronchoalveolar fluid (BALf)
To further assess the mucosal responses induced by BLP-IpaB/D immunization, we 
measured the frequency of IpaB- and IpaD-specific ASC in the nasal-associated lymphoid 
tissue (NALT) and lung, as well as the levels of IpaB/D-specific IgG and IgA in BALf, one 
week after the 3rd and final immunization (Figures 5a and b). High numbers of IpaB-specific 
IgG ASC were detected in the NALT of BLP-IpaB/D vaccinated mice (Figure 5a). An even 
higher IpaB-specific ASC response was found in the lungs (Figure 5b). Likewise, IpaD-
specific IgG ASC were detected in the lungs, albeit at much lower numbers. IpaB and IpaD-
specific IgA ASC were induced in response to BLP-IpaB/D, but their magnitude was 
marginal compared to the IgG ASC. In all cases, the ASC responses in the BLP-IpaB/D 
group surpassed those of mice that received IpaB/D alone. Elevated IpaB- and IpaD-specific 
IgG titers were found in BALf, and, similar to the ASC, there was a trend of higher 
responses in the BLP-IpaB/D recipients compared to those immunized with IpaB/D alone 
(Figure 5c). No specific antibodies or ASC were detected in the BLP and PBS controls. A 
summary of serum and mucosal antibody responses in all groups and the corresponding 
protection levels is given in Table 2. From a large panel of cytokines measured by 
microarrays (IFN-γ, IL-10, IL-12, IL-2, IL-4, IL-5, KC, and TNF-α) IL-1β, IL-12 and the 
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neutrophil-attracting chemokine, keratinocyte chemoattractant (KC), were found to be 
elevated in the BALf of vaccinated mice (Figure 5d). The highest levels were found in the 
group immunized with BLP-IpaB/D, but positive responses (above the unvaccinated PBS 
controls) were also found in the IpaB/D and BLP groups (Figure 5d).
Systemic ASC responses and bone marrow adoptive transfer protection
We also examined the presence of antigen-specific ASC in the spleen and in the bone 
marrow (BM) as potential sources of circulating antibodies and long-lived plasma cells, 
respectively. IpaB- and IpaD-specific IgG and IgA ASC were found in both tissues mainly 
in response to BLP-IpaB/D vaccination, whereas no ASCs were detected after vaccination 
with IpaB/D alone (Figures 6a and b). In most instances, the levels of IgG ASC surpassed 
those of IgA ASC. BM cells from BLP-IpaB/D recipients adoptively transferred to naïve 
mice conferred moderate, yet significant protection against lethal Shigella infection; 40% of 
the BM recipients survived the pulmonary challenge (Figure 6c).
Antibody responses and protective efficacy of BLP-IpaB/D in newborn mice
Considering that infants and toddlers would be the main targets of a Shigella vaccine and 
that immune responses may be influenced by age and immune development, we examined 
the protective capacity of BLP-IpaB/IpaD in mice immunized as newborns and infants. 
Seven-day-old mice were administered BLP-IpaB/D or IpaB/D via the nasal route and 
identical booster doses were given on days 14, 21 and 28 after birth. A series of preliminary 
studies was performed to determine optimal doses and number of booster immunizations 
needed to maximize protection. Because the serum IgG anti-IpaD levels were consistently 
low, the amount of IpaD was increased to the highest that could be included in the vaccine 
inoculum (24 μg in 10 μl). A three-dose regimen with BLP-IpaB/D, which was highly 
successful in adults, provided only ~40% protection in mice immunized as newborns (data 
not shown) and hence a fourth dose was added after weaning (day 28). Immunization with 
BLP-IpaB/D during the neonatal/infant period resulted in significant levels of IpaB- and 
IpaD-specific serum IgG. As observed in adult mice, antibody responses markedly increased 
when the Ipas were displayed on the BLP. Immunization with BLP-IpaB/D elicited serum 
IgG responses against both IpaB and IpaD, whereas lower IpaB- and barely significant (and 
delayed) IpaD-specific IgG was produced in response to IpaB/D alone (Figure 7a). 
Newborn/infant immunization with BLP-IpaB/D afforded 90% protection against S. flexneri 
2a and 44% against S. sonnei, which in both cases was significant above the unvaccinated 
controls (Figure 7b). Protection was greatly reduced upon immunization with IpaB/D alone; 
only 30% of these mice survived S. flexneri challenge and only 11% survived infection with 
S. sonnei.
DISCUSSION
The recent estimates of moderate-to-severe diarrhea attributable to Shigella spp. in children 
living in Asia and sub-Saharan Africa1 re-emphasize the urgent need for effective preventive 
strategies to reduce mortality rates and alleviate an overall disease burden that results in 
long-lasting health impairment. Herein, we provide the first report of successful 
immunization of adult and newborn/infant mice with L. lactis BLP displaying Shigella IpaB 
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and IpaD. The vaccine was well tolerated when administered via the nasal route as early as 
one week after birth and induced robust immune responses. Most importantly, it was highly 
protective against lethal challenge with S. flexneri 2a and S. sonnei 53G, the two most 
prevalent endemic serotypes in the developing world as reported by the GEMS18 and 
previous large-scale studies.19,20 Immunogenicity and protection were dose-dependent and 
consistent in multiple experiments using different vaccine lots. The safety and suitability of 
the BLP-IpaB/D vaccine for mucosal delivery and its capacity to induce strong cross-
protective immunity in young hosts make it unique and appealing for the immunization of 
toddlers and young children, who would benefit the most from a practical and effective 
prophylactic approach.
The BLP exhibited distinct adjuvant properties and contributed to the protective immunity 
achieved. Display of IpaB and IpaD on the L. lactis particles significantly increased the 
magnitude of systemic and mucosal antibody and ASC responses, innate immune mediators 
in mucosal secretions and importantly, the survival rate post challenge. It is noteworthy that 
robust serum IgG responses to IpaD, typically the less immunogenic of the two proteins, 
were only elicited when it was displayed on the BLP. Similarly, stool IgA was detected only 
in mice that received BLP-IpaB/D, not in the IpaB/D recipients. This immune enhancement 
could be explained by a more efficient B cell activation and antigen delivery to APC, and/or 
by the inherent adjuvant properties of the BLP.21,22 Displayed on the BLP surface, the 
proteins are less likely to suffer degradation and, due to the microbial size and surface 
charge of the particles, they are more easily captured by activated APC than soluble proteins 
alone.10,23 We have shown that the L. lactis BLP bind TLR2 in vitro and activate adult and 
neonatal dendritic cells (from both mice and humans), enhance their maturation and capacity 
for antigen presentation and stimulate the production of pro-inflammatory cytokines 
including TNF-α and IL-6.10 Similarly, the interaction of BLP with TLR2 in vivo has been 
associated with the induction of mucosal IgA responses, as well as splenic IgG ASC and 
IFN-γ-secreting T cells following co-administration of a split influenza virus vaccine.11
The immunological effectors and the precise mechanisms by which IpaB and IpaD mediate 
protection against Shigella lethal pulmonary infection in the mouse model are not fully 
understood. Presumably, antibodies produced locally and/or transudated from circulation 
impede bacterial-host cell contact (and inhibit translocation of virulence factors) at the 
mucosal epithelial interface, thereby preventing tissue damage and bacterial spread.4,6 
Antibodies may also facilitate uptake of organisms by phagocytic cells. A detailed statistical 
analysis of BLP-IpaB/D and IpaB/D-induced antibodies and rates of survival from multiple 
experiments revealed a categorical association between a serum antibody response to each 
of the proteins and protection against lethal experimental challenge. Survival was also 
associated with the magnitude of serum IgG (and IgG2a) ELISA titers; the stronger the 
antibody response, the higher the likelihood of vaccinated mice withstanding the lethal 
infection, with threshold serum IpaB- and IpaD-specific IgG titers of 1×105 EU ml−1 
predicting at least 60% survival.
A new and critical observation was the capacity of IpaB and IpaD antibodies generated 
through vaccination to reduce Shigella-induced macrophage cytotoxicity and facilitate their 
uptake of bacteria through opsonophagocytosis. These functional properties are important to 
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prevent tissue damage and further microbial spread during Shigella infection, and might 
represent mechanisms of host defense in vivo. Antibodies generated by the BLP-IpaB/D 
vaccine elicited higher OPA activity (P<0.01), which could be explained by the larger 
proportion of IgG2a induced, compared to the Ipas alone. Unlike IgG1, IgG2a binds the 
FcγRI receptor on mouse macrophages and phagocytic cells24 with high affinity and is 
therefore more efficient at activating these cells and promoting microbial clearance. In line 
with these results, we and others had shown that the BLP promote more balanced Th1/Th2 
responses to the carried antigens compared with the same antigens given alone or admixed 
with alum, which generate a distinct Th2-biased IgG1 response10,17 that is unsuited for the 
elimination of intracellular pathogens, particularly in the Th2-prevailing environment early 
in life.25
Among the systemic effectors induced by BLP-IpaB/D immunization, it is worth mentioning 
the IpaB and IpaD-specific BM ASC (representing long-lived plasma cells or their 
plasmablasts precursors) that partly protected naïve hosts, as this suggests the potential for 
this vaccine to elicit effectors that can mediate long-lasting protective immunity. In addition, 
the BLP-IpaB/D generated potent mucosal immune responses largely represented by IpaB 
and IpaD-specific IgG ASC in the NALT and lungs, and high levels of IpaB and IpaD-
specific IgG in BALf. Some of the antibodies detected in the BALf were absent in serum 
(i.e., IgA and IpaD-specific IgG in IpaB/D recipients), which suggests that vaccine-induced 
local ASC produce some of the mucosal antibodies detected. An interesting observation was 
the predominance of IgG responses in mucosal tissues (NALT and lung ASC, and BALf) as 
opposed to IgA, which was still sufficient to confer high levels of protection. In humans, 
serum IgG specific for Shigella LPS has been associated with serotype-specific 
protection 26–30 and it has been proposed that these antibodies transudate the mucosal 
epithelial barrier and neutralize and/or kill the organisms in the gut lumen.31 The relative 
contribution of serum and mucosal antibodies in protection against shigellosis and the 
mechanisms involved remain to be elucidated.
Another relevant observation was the presence of innate immune mediators (IL-12, IL-1β 
and mKC) in lung secretions from BLP-IpaB/D recipients. IL-12 plays a major role in host 
defense against intracellular pathogens by activating macrophages and inducing IFN-γ 
production. Likewise, KC (CXCL1), a chemokine produced by macrophages and 
neutrophils (via TLR2 activation pathway), recruits and activates phagocytic cells. Shigella 
IpaB has been attributed with initiating the inflammatory response through caspase-1, by 
promoting secretion of IL-1β.32 In a concerted manner, these molecules can facilitate 
bacterial clearance synergizing with host adaptive immune effectors. This is, to the best of 
our knowledge, the first demonstration of these cytokines/chemokines being present in 
mucosal secretions following immunization with a Shigella or BLP vaccine.
In an attempt to identify the tissues involved in vaccine uptake, we tracked the in vivo 
distribution of i.n. delivered fBLP. The particles localized in the NALT the first few hours 
after inoculation and subsequently in the gut; they were also found in the lungs for up to at 
least 24 hours. Antigen-specific ASC were detected in NALT and lung, and it is therefore 
reasonable to assume their involvement in immunological priming. The 30 μl inoculum 
volume administered is consistent with particles spreading from the nasal cavity into the 
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lungs, as we have observed in mice given live bacterial vaccines33. Others have similarly 
reported >10 μl intranasal instillations dispersing into the bronchial region as well as the 
gastrointestinal tract.34 However, in humans, delivery of a BLP vaccine would be directed to 
the nasal cavity targeting the NALT as the primary inductive site. The fBLP presumably 
reached the gut through the swallowing reflex and this likely represents the route excretion. 
However, some immune activation might have occurred there as well, as suggested by the 
presence of IgA in stool, while completely absent in circulation. Since Shigella is an enteric 
pathogen, immunological priming in the gut and induction of local (intestinal) immunity 
would be an advantageous feature of any new vaccine. We had previously reported that oral 
delivery of IpaB and IpaD resulted in lower protective efficacy than intranasal vaccination4 
and therefore this route was not pursued in the BLP-IpaB/D studies. Since experimental 
infection of mice with Shigella involves nasal/pulmonary exposure (as opposed to enteric in 
humans), oral vaccination adds a confounding factor to the proper evaluation of vaccine 
candidates in this model.
An additional important benefit of the BLP technology is that it allows for successful 
mucosal (even intranasal) immunization, without the need for potentially reactogenic 
adjuvants. In previous work from our group, IpaB/D delivered i.n., admixed with a double 
mutant of the Escherichia coli heat labile toxin (dmLT), afforded similar protection to that 
described here for the BLP-IpaB/D, using a smaller dose. However, due to safety concerns, 
an enterotoxin-derived adjuvant would not be suitable for use in humans.35 Parenteral 
immunization with the IpaB/D plus dmLT was likewise effective in mice6 and potentially 
suitable for use in children; a drawback is that it would still require special tools (i.e. 
microneedles) and might not be as practical as mucosal delivery. The BLP were well 
tolerated when given to 15 human adults via the nasal route (1.25 mg of BLP in 250 μl) 
mixed with a commercial influenza vaccine.21 If equally safe in children, this route might 
provide an alternative to oral vaccination, which is known to yield less than desired immune 
responses to routine vaccines in developing countries.36 Supportive of this concept are the 
results of Mallet et al37 and Orr et al38, whereby intranasal immunization with a 
proteosome-based S. sonnei and S. flexneri vaccine induced homologous protection in mice 
and in the guinea pig keratoconjunctivitis model, respectively. While none of these models 
accurately represent the course of Shigella infection in humans, these results confirm the 
potential of a mucosal/ intranasal subunit vaccine approach.
Pre-clinical studies of Shigella vaccine candidates have traditionally involved immunization 
of adult hosts. Two recent reports investigated protection of young animals through passive 
protection from maternally derived antibodies.39,40 Gnobiotic piglets have been used to 
evaluate live vaccine strains.41 Ours is, to the best of our knowledge, the first demonstration 
of substantial cross protective immunity in mice immunized as newborns with a protein-
based vaccine. Although the protection against S. sonnei was lower than anticipated, it could 
be improved through optimization of vaccine dose and regimen; it may also reflect a more 
stringent challenge procedure.
In conclusion, the BLP-IpaB/D vaccine is a promising candidate for immunization of young 
children against shigellosis. Advantages of this vaccine over other approaches include its 
safety, suitability for mucosal delivery (which makes it a practical for large scale use), 
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strong immunogenicity and broad protective capacity. Our results warrant further 
assessment of this concept in humans.
METHODS
Preparation of vaccines and antigens
Recombinant IpaB and IpaD were purified by affinity and size exclusion chromatography as 
previously described.5,42 To be loaded onto the L. lactis BLP particles (formerly called 
Gram Enhancement Matrix particles), each protein was expressed as a fusion containing the 
peptidoglycan anchoring (PA) domain (IpaB-PA and IpaD-PA). The plasmid construction, 
expression and purification of IpaD-PA has been described elsewhere.43 IpaB-PA was 
produced by inserting the DNA sequence for PA 5′ to the ipaB sequence in pACYC-Duet as 
previously described.44 The purification of IpaB-PA was the same as for IpaB. L. lactis BLP 
were produced by boiling L. lactis whole cells in 10% trichloroacetic acid for 30 min, 
followed by extensive washing in PBS, as previously described.8 One mg of BLP contains 
approximately 8×109 particles. To produce BLP-IpaD, L. lactis cell-free culture 
supernatants containing IpaD-PA and BLP were mixed under gentle rotation for 30 min at 
room temperature as described elsewhere.8 To produce BLP-IpaB, BLP were incubated with 
purified IpaB-PA for 30 min with gentle rocking at room temperature. Removal of excess 
IpaB or IpaD-PA was achieved by three sequential centrifugation of the particles, removal 
of the supernatants, and resuspension. The resulting vaccine preparations BLP-IpaB and 
BLP-IpaD (along with IpaB and IpaD alone) were analyzed by Sodium Dodecyl Sulfate-
Polyacrylamide Gel Electrophoresis (SDS PAGE). Samples were diluted 1:2 in Laemmli 
sample buffer® (BioRad, Hercules, CA) containing 5% 2β-Mercaptoethanol, boiled at 95°C 
for 10 min and loaded (1 μg/well) in a 4–12% pre-casted Mini-PROTEAN TGX Gel® 
(BioRad, Hercules, CA). The separated proteins were detected by Coomassie staining (EZ 
blue™) (Sigma, St. Louis, MO). The amount of IpaB-PA and IpaD-PA bound to the BLP 
was determined by SDS PAGE using IpaB-PA or bovine serum albumin as standard, 
respectively. The BLP-IpaB/D and IpaB/D vaccine components were stored at −80°C until 
use.
The BLP-IpaB and BLP-IpaD were further analyzed by dual color immunofluorescence. 
Briefly, suspensions containing 100 μl of BLP-IpaB and BLP-IpaD were washed with 
ultrapure water (Milli-Q, Millipore, Billerica, MA), resuspended in PBS containing 2% 
Bovine serum albumin (BSA, Sigma, St. Louis, MO) and incubated for one hour at room 
temperature with biotinylated mouse anti-IpaB or anti-IpaD monoclonal antibodies (a gift 
from Dr. Ed Oaks). After washing, BLP-IpaD samples were incubated with anti-mouse 
Alexa Fluor® 488 (Molecular Probes, Grand Island, NY) and BLP-IpaB samples with 
Streptavidin Alexa Fluor® 598 (Molecular Probes, Grand Island, NY); 1:50 and 1:200, 
dilutions, respectively, in PBS containing 2% BSA for one hour at room temperature. After 
washing, samples were resuspended in 100 μl of ultrapure water, and a 10-μl sample was air 
dried onto a microscope slide and applied ProLong® Gold antifade reagent (Life 
Technologies, Eugene, OR) along with a coverslip. Images were acquired at 100× 
magnification on a Zeiss Axio Imager Z.1 fluorescence microscope using ZEN Imaging 
Software (Carl Zeiss Microscopy, Oberkochen, Germany).
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In vivo tracking of L. lactis BLP
The BLP particles were labeled with Alexa Fluor® 790 Succinimidyl Esters (NHS esters) 
purchased from Molecular Probes, Grand Island, NY, through chemical binding to non-
protonated aliphatic amine groups on the particle surface. Briefly, the BLP (15 mg) were 
washed and resuspended in 0.1M NaHC03 pH 8.3, and incubated with 1 μg of Alexa Fluor® 
790 for 1 h at 4°C in the dark and with agitation. Adequate labeling (>80%) was confirmed 
by flow cytometry. The fluorescent BLP (fBLP) were washed three times in PBS and 
resuspended to a final concentration of 10 mg ml−1 in PBS containing 0.01% thimerosal 
(Sigma-Aldrich, St. Louis, MO). Adult female Balb/c mice (Charles River Laboratories, 
Wilmington, MA) were placed in an anesthesia induction chamber (Piramal Healthcare, 
Mumbai, Maharashtra, India) dispensing Isoflurane (Fluriso™, VETone®, Boise, ID) 2.5% 
and, once fully anesthetized, 30 μl of fBLP (0.3mg) were administered i.n. The mice were 
then moved to the imaging chamber of a Xenogen IVIS-200 system (Perkin Elmer, 
Waltham, MA) and placed lying on their backs on a heated shelf surface to maintain body 
temperature. Isoflurane (0.5%) was administered through nose cones during imaging. 
Pictures were taken and analyzed using Living Image® Software Version 4.3.1 (Perkin 
Elmer), creating gates or Regions of Interest (ROIs). The fluorescent intensity (Epi-
fluorescence) of the fBLP was measured as radiant efficiency using the flowing equation: 
. The background was defined as the ROI 
(nasal tissue, lungs or intestine) of mice that received unlabeled BLP.
Immunization, cell adoptive transfer and experimental infection
Female Balb/c adult mice (7–8 weeks old) were immunized i.n. on days 0, 14 and 28 with 
increasing doses of BLP-IpaB and BLP-IpaD or IpaB and IpaD (alone): 2.5 μg IpaB and 10 
μg IpaD, referred to as BLP-IpaB/D-Low; 5 μg IpaB and 20 μg IpaD (BLP-IpaB/D-Med); 10 
μg IpaB and 40 μg IpaD (BLP-IpaB/D-High), and 20 μg of IpaB and 53 μg of IpaD (BLP-
IpaB/D-Max). The amount of BLP given with each vaccine was consistently 300 μg. The 
Max dose was the largest amount of BLP-IpaB/D that could be given in the 30 μl inoculum 
volume. Other groups received equivalent doses of IpaB and IpaD (without BLP), also 
referred to as IpaB/D-Low, IpaB/D-Med, IpaB/D-High and IpaB/D-Max, respectively. 
Newborn (7-days old) mice received 2 μg IpaB and 24 μg IpaD alone or displayed onto the 
BLP (in a 10 μl volume), on days 7, 14, 21 and 28 after birth. In both experiments, 
unvaccinated controls received BLP alone or PBS. The vaccine inoculum was dispensed half 
into each nare, with a pipette and under Isoflurane anesthesia, as previously described.4 
Serum and fecal samples were obtained from individual mice before and every two weeks 
after vaccination. Bronchoalveolar lavage fluid, NALT, spleen and BM cells were collected 
from subgroups of mice at days 35 or 69 as described before.4,5 For adoptive transfer 
experiments, BM cells obtained on day 69 post-vaccination were injected i.v. to adult mice; 
6×107 cells in 100 μl of PBS were administered to each recipient via the tail vein. One 
month after the last immunization (day 56) or 48 h after cell adoptive transfer, adult mice 
were challenged with 6×107 CFU virulent S. flexneri 2a 2457T (corresponding to ~11 
MLD50) or with 1.3×108 CFU of S. sonnei 53G (corresponding to ~6 MLD50), as previously 
described.4,5 Newborn mice were challenged with 3×107 CFU of S. flexneri 2a 2457T 
(corresponding to ~3 MLD50) or with 9.35×107 CFU of S. sonnei 53G. All animal studies 
Heine et al. Page 11













and procedures were approved by the University of Maryland Institutional Animal Care and 
Use Committee.
Antibody measurements
(i) ELISA IpaB- and IpaD- specific antibodies were measured by ELISA as previously 
described. 4,5 (ii) Opsonophagocytosis. A Shigella opsonophagocytic assay was developed 
following previously described format45, with modifications. Briefly, J774A.1 mouse 
macrophages were seeded into 24-well plates (2×105 cells per well) and grown in 
Dulbecco’s modified Eagle Medium (DMEM) (Gibco, Grand Island, NY) supplemented 
with 10% Defined Fetal Bovine Serum (GE Healthcare HyClone, Logan, UT) at 37°C, 5% 
CO2, until they reached 90% confluence. S. flexneri 2a wild type strain 2457T was grown 
overnight at 37°C in Tryptic Soy Agar (TSA) (Difco, Becton Dickinson Diagnostics, 
Sparks, MD) supplemented with 0.02% Congo Red (Sigma-Aldrich), and isolated colonies 
were sub-cultured in Animal-Product-Free Luria Bertani broth (Lennox) (Athena Enzyme 
Systems, Baltimore, MD) and grown at 37°C until reaching an optical density measured at a 
600 nm wavelength (OD600) of 0.2. Ninety μl bacterial suspension containing ~ 2–3×105 
CFU were incubated with 10 μl of individual serum samples (previously inactivated for 20 
min at 56°C) for 20 min at room temperature, in constant rotation. A 10 μl aliquot of 
opsonized organisms (2–3×104 CFU) was added to the cell monolayers (in duplicate wells), 
centrifuged (10 min, 1,000 × g) and incubated for 45 min. After washing with PBS, 500 μl 
of fresh medium containing 100 μg ml−1 of gentamicin (Gibco) was added for 1 h to remove 
external organisms. Cells were washed again, lysed with 500μl of PBS containing 0.5% 
Triton X-100 (Sigma-Aldrich) and supernatants (25 μl aliquots, in triplicate) were cultured 
overnight at 37°C in TSA-Congo Red to determine viable counts. The percent of 
phagocytosis was calculated as the ratio of CFU recovered/CFU added to the wells × 100. 
(iii) Neutralization of macrophage cytotoxicity. Shigella is known to induce apoptosis of 
macrophages.46 To determine whether serum from immunized animals could prevent 
macrophage cytotoxicity upon exposure to wild-type organisms, we established a 
cytotoxicity neutralization assay based on methods previously described.47–49 A 30 μl 
suspension of S. flexneri 2a strain 2457T, prepared as described above and containing 2×105 
CFU, was incubated with 10 μl of mouse serum in 96-wells round bottom plates (in 
duplicate) for 20 min at room temperature. The content of each well was then transferred to 
a 96-well plate seeded with J774A.1 macrophages (3×103 per well, moi: 60) and incubated 
for 18 h at 37°C, 5% CO2. The plate was centrifuged and lactate dehydrogenase (LDH) 
release (an indicator of cytotoxicity) was measured in 50 μl of culture supernatants using a 
colorimetric assay (CytoTox 96, Promega, Madison, WI). Absorbances values at 490 nm 
were measured using a Multiskan ELISA reader (Thermo Scientific). Cytotoxicity (cell 
death) was determined as: (experimental LDH release–spontaneous LDH release)/
(maximum LDH release–spontaneous LDH release), where spontaneous LDH release was 
the LDH activity in supernatants from cells incubated in medium alone and total LDH 
release the activity in lysed macrophages. Percent neutralization was calculated as 1-cell 
death ×100.
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IgA and IgG ASC were measured by ELISpot as previously described.4,5 Cytokines were 
measured in alveolar lavages or in culture supernatants from cells stimulated with IpaB or 
IpaD, using a MSD® Mouse Th1/Th2 Multi-array® tissue culture kit (Meso Scale 
Discovery, Rockville, MD), as previously described.4,6
Statistical analysis
Overall differences over time in % fluorescence and antibody responses (in serum and stool) 
were assessed by multivariate analysis of variance (MANOVA), using the different each 
time points measured as variables. Comparisons between vaccinated groups at specific time 
points were made using one-way analysis of variance (ANOVA) with the Tukey-Kramer 
multiple comparisons test. Survival for serum IgG responders (titers ≥ 50 ELISA Units 
ml−1) and non-responders (<50 ELISA Units ml−1) and stool IgA responders (titers ≥ 10 
ELISA Units ml−1) and non-responders (<10 ELISA Units ml−1) were analyzed by a Fisher 
exact test, with the two-sided p-value calculated as twice the one-sided p-value in the 
direction of the observed difference. Associations between probability of survival and serum 
IgG titers were evaluated using logistic regression models. Survival after challenge was 
assessed by Kaplan-Meier curves and log-rank tests. Two-sided P≤0.05 was considered 
statistically significant. GraphPad Prism 6 software (GraphPad Software, Inc., La Jolla, CA), 
SAS version 9.3 (SAS Institute, Cary, NC) and NCSS 8 (Number Cruncher Statistical 
Systems, Kaysville, UT) were used for statistical analyses.
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Figure 1. Analysis of BLP-IpaB/D by SDS-PAGE and fluorescence microscopy
(a) SDS PAGE analysis of BLP displaying IpaB (BLP-IpaB) or (b) IpaD (BLP-IpaD). The 
size of molecular weight markers (in kDa) is shown on the left (MWM). Proteins were 
stained with Coomassie blue. (c) Immunofluorescence (top) and bright field microscopy 
images (bottom) of BLP-IpaB, BLP-IpaD and BLP alone. BLP display of IpaB and IpaD 
was revealed by incubation with specific monoclonal antibodies: biotin labeled anti-IpaB 
followed by Streptavidin-Alexa Fluor® 594 (red) and unlabeled anti-IpaD followed by anti-
mouse Alexa Fluor® 488 (green).
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Figure 2. In vivo imaging of L. lactis BLP distribution
(a) Unlabeled and fluorescent BLP (fBLP) were administered i.n. to adult mice in a 30 μl 
volume, under anesthesia, and whole body images were obtained at the indicated time points 
using a Xenogen IVIS-200 imagining system. (b) Fluorescence distribution among different 
organs. Each bar represents mean % of total fluorescence+ SEM from 3 mice per time point; 
total fluorescence was the radiant efficiency of fBLP in the 30-μl inoculum. Significant 
overall differences were determined by multivariate analysis of variance (MANOVA), with 
% fluorescence at each time point as the variable. Comparisons between fBLP and BLP 
were then made at each individual time point using one-way ANOVA with Dunnett’s 
comparison to a common control (BLP alone); * denotes statistical significance P<0.05 
compared to unlabeled BLP.
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Figure 3. Serum IgG, stool IgA and protective efficacy of BLP-IpaB/D and IpaB/D in adult mice
Adult mice were immunized i.n. with increasing dosage levels (maximum, high, medium 
and low) of BLP-IpaB/D or IpaB/D alone: BLP carrying 20 μg IpaB and 53 μg IpaD (BLP-
IpaB/D-Max), 10 μg IpaB and 40 μg IpaD (BLP-IpaB/D-High), 5 μg IpaB and 20 μg IpaD 
(BLP-IpaB/D-Med), and 2.5 μg of IpaB and 10 μg of IpaD (BLP-IpaB/D-Low). The same 
amounts of IpaB and IpaD were given alone. (a) Kinetics of IpaB and IpaD serum IgG (b) 
and stool IgA titers measured by ELISA. Each data point represents the geometric mean titer 
in log10 of at least 10 mice per group ± SEM. (c) Mice were challenged with wild-type S. 
flexneri 2a 2457T or S. sonnei 53G 28 days after the third immunization; the curves 
represent % survival post-challenge for 10 mice per group. (d) Serum IgG titers and (e) 
protection following S. flexneri challenge in mice immunized with BLP-IpaB/D-Max or 
IpaB/D alone in 2 separate experiments. Significant overall differences in log10 antibody 
titers were determined by MANOVA. Significant differences in titers between all vaccinated 
groups were analyzed by ANOVA with Tukey-Kramer multiple comparison test to compare 
all groups. * P<0.05 for mean antibody titers significantly higher compared to all other 
groups (panels a and b) and compared to Ipas alone and controls (panel d). Significant 
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differences in survival curves were determined by log-rank test; * P<0.05 compared to PBS 
and BLP.
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Figure 4. Antibodies and protection analysis, functional activity (opsonophagocytosis and 
neutralization of cytotoxicity) and IgG subclasses
Mice were immunized with BLP-IpaB/D or IpaB/D Max (20 μg IpaB and 53 μg IpaD), as 
described in Figure 3. (a) Antibody titers measured before challenge and ranked according 
to survival outcome; circles denote mice immunized with BLP-IpaB/D, and squares mice 
immunized with IpaB/D. Higher levels of IpaB or IpaD-specific serum IgG were associated 
with protection (survival) by logistic regression on log10-transformed IpaB or IpaD titers; * 
denotes P < 0.001 by likelihood ratio test in both analyses. (b) Estimated survival 
probability by logistic regression on log-transformed IpaB or IpaD IgG titers (same analysis 
as for panel a); mice immunized with BLP-IpaB/D-Max and IpaB/D-Max were included and 
depicted as circles and square, respectively. Filled and solid circles represent surviving and 
non-surviving mice, respectively. Dashed lines indicate level of antibodies predicting >60% 
survival. (c) Opsonophagocytic activity of serum antibodies from vaccine and control 
groups. Results are shown as mean % opsonophagocytic uptake of S. flexneri 2a 2457T in 
individual serum samples. (d) IpaB- and IpaD-specific IgG1 and IgG2a subclasses 
determined by ELISA; data represent mean titers from 20 mice per group. (e) Neutralization 
of macrophage cytotoxicity by serum from different treatment groups. Results are shown as 
mean % neutralization from replicate wells by pooled serum samples. In panels c and d, 
individual measurements from vaccine and control groups were compared by one-way 
ANOVA with Dunnett’s multiple comparisons test against a common control; the tests on 
IpaB- and Ipa-D-specific subclasses were done using log10-transformed antibody titers. * 
denotes P < 0.05 compared to non-serum or PBS for OPA and to PBS for subclasses.
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Figure 5. Mucosal IgA and IgG secreting cells, antibodies and cytokines following BLP-IpaB/D 
and IpaB/D vaccination
Mice were immunized with BLP-IpaB/D or IpaB/D Max dose as described in Figure 3. IgA 
and IgG ASC were measured by ELISpot in the (a) NALT and (b) lung tissue 35 days after 
the first immunization. Data correspond to mean ASC counts per 106 cells measured in 
pooled cell suspensions from 5 mice in each group + SEM from triplicate wells. (c) IpaB- 
and IpaD-specific IgG and IgA were measured by ELISA in bronchoalveolar lavage fluid 
(BALf) 35 days after immunization; data represent mean of individual titers from 5 mice per 
group (d). Cytokines measured in BALf by MSD multiarray technology; data represent 
mean concentrations as (pg ml−1) + SEM from triplicate wells.
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Figure 6. Systemic IgG and IgA ASC and induced by the BLP-IpaB/D and IpaB/D and 
protection by bone marrow adoptive transfer
Mice were immunized with BLP-IpaB/D or IpaB/D-Max as described in Figure 3. (a) IgA 
and IgG ASC measured by ELISpot in spleen and (b) bone marrow (BM) on day 69 after 
primary immunization. Data correspond to mean ASC counts per 106 cells from pooled cell 
suspensions from 5 mice in each group + SEM from triplicate wells. (c) Bone marrow cells 
from BLP-IpaB/D or PBS recipients (obtained 69 days after primary vaccination) were 
adoptively transferred to naïve mice that were challenged 48 h later with wild type S. 
flexneri 2a 2457T. Survival curves were compared by log-rank test; * P<0.05 compared to 
PBS.
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Figure 7. Serum IgG levels and protective efficacy of BLP-IpaB/D and IpaB/D in newborn mice
Mice were immunized as newborns and infants with BLP carrying 2 μg IpaB and 24 μg 
IpaD or with the same amounts of IpaB and IpaD given alone. Control groups received BLP 
alone or remained naïve. Vaccines were given on days 7, 14, 21 and 28 after birth (arrows). 
(a) IpaB- and IpaD-specific IgG measured by ELISA; data represent geometric mean titers 
from 12 mice per group. Significant overall differences in log10 antibody titers were 
determined by MANOVA. Significant differences in titers between all vaccinated groups 
were analyzed by ANOVA with Tukey-Kramer multiple comparison test to compare all 
groups. * P<0.05 for mean antibody titers significantly higher compared to BLP and PBS 
control groups. # P<0.05 for mean antibody titers significantly higher compared to all 
groups. (b) Protection against lethal pulmonary infection with wild type S. flexneri 2a 2457T 
or S. sonnei 53G (n=12). Survival curves were compared by log-rank test. * P<0.05 
compared to naïve mice. # P<0.05 compared to all groups.
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